Top

29-07-2024 | Metabolic Dysfunction-Associated Steatotic Liver Disease | REVIEW

Assessing the Therapeutic Potential of Fecal Microbiota Transplantation in Steatotic Liver Disease: Current Insights and Future Pathways

Authors: Carolina Jiménez-González, Ignacio Vallejo, David Sordo, Juan Manuel Medina-Méndez, Marta Alonso-Peña, Javier Crespo

Published in: Current Hepatology Reports

Abstract

Purpose of Review

To explain the relevance of Fecal Microbiota Transplantation (FMT) for the treatment of MASLD, the scientific evidence supporting its usefulness, and the difficulties of its translation into effective treatments for use in routine clinical practice.

Recent Findings

FMT has been proven effective and safe in other indications and several procedures have been tested for delivery of fecal microbiota to the intestine. The field awaits results from ongoing clinical trials to better understand the role of FMT in the management of MASLD.

Summary

The pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is multifaceted, involving an intricate interaction among genetic predisposition, diet, environmental factors, lifestyle choices, and the gut microbiota (GM). The complexity of these interactions may explain the difficulties to obtain an effective pharmacological treatment for MASLD.

Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-2817.e28. https://doi.org/10.1016/j.cgh.2021.12.002.CrossRefPubMed

Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural History of Nonalcoholic Fatty Liver Disease: A Prospective Follow-Up Study With Serial Biopsies. Hepatol Commun. 2017;2(2):199–210. https://doi.org/10.1002/hep4.113.CrossRefPubMedPubMedCentral

Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021;18(10):5227. https://doi.org/10.3390/ijerph18105227.CrossRefPubMedPubMedCentral

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497–509. https://doi.org/10.1056/NEJMoa2309000.CrossRefPubMed

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra^TM (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis —Full text view— https://www.madrigalpharma.com/. Available online: https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm (Accessed on 25 March 2024).

Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–24. https://doi.org/10.1053/j.gastro.2014.01.020.CrossRefPubMed

Forlano R, Sivakumar M, Mullish BH, Manousou P. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. Int J Mol Sci. 2022;23(15):8307. https://doi.org/10.3390/ijms23158307.CrossRefPubMedPubMedCentral

King CH, Desai H, Sylvetsky AC, LoTempio J, Ayanyan S, Carrie J, et al. Baseline human gut microbiota profile in healthy people and standard reporting template. PLoS ONE. 2019;14(9):e0206484. https://doi.org/10.1371/journal.pone.0206484.CrossRefPubMedPubMedCentral

Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. Lipids Health Dis. 2021;20(1):22. https://doi.org/10.1186/s12944-021-01440-w.CrossRefPubMedPubMedCentral

10.

Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016;23(6):32002. https://doi.org/10.1038/srep32002.CrossRef

11.

Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A role for gut microbiome fermentative pathways in fatty liver disease progression. J Clin Med. 2020;9(5):1369. https://doi.org/10.3390/jcm9051369.CrossRefPubMedPubMedCentral

12.

Bauer KC, Littlejohn PT, Ayala V, Creus-Cuadros A, Finlay BB. Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective. Gastroenterology. 2022;162(7):1858-1875.e2. https://doi.org/10.1053/j.gastro.2022.01.058.CrossRefPubMed

13.

Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, et al. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: Recent updates. Int J Biol Sci. 2021;17(3):818–33. https://doi.org/10.7150/ijbs.56214.CrossRefPubMedPubMedCentral

14.

Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: A new insight into therapeutic strategies. Nutrients. 2019;11(11):2642. https://doi.org/10.3390/nu11112642.CrossRefPubMedPubMedCentral

15.

Smits LP, Bouter KEC, De Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946–53. https://doi.org/10.1053/j.gastro.2013.08.058.CrossRefPubMed

16.

Del Barrio M, Lavín L, Santos-Laso Á, Arias-Loste MT, Odriozola A, Rodriguez-Duque JC, et al. Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2023;24(7):6123. https://doi.org/10.3390/ijms24076123.CrossRefPubMedPubMedCentral

17.

Ensayos Clínicos Sobre Pacientes Con Esteatohepatitis No Alcohólica: Grupo 1 o Grupo Experimental, Grupo 2 o Grupo de Control—Registro de Ensayos Clínicos—ICH GCP. Available online: https://ichgcp.net/es/clinical-trials-registry/NCT05622526 (Accessed on 25 March 2024).

18.

Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr. 2019;110(1):139–49. https://doi.org/10.1093/ajcn/nqz042.CrossRefPubMedPubMedCentral

19.

Fang T, Wang H, Pan X, Little PJ, Xu S, Weng J. Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies. Int J Biol Sci. 2022;18(15):5681–97. https://doi.org/10.7150/ijbs.65044.CrossRefPubMedPubMedCentral

20.

Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787–94. https://doi.org/10.1136/gutjnl-2012-303816.CrossRefPubMed

21.

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. N Nature. 2012;482(7384):179–85. https://doi.org/10.1038/nature10809.CrossRefPubMed

22.

De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014;59(5):1738–49. https://doi.org/10.1002/hep.26695.CrossRefPubMed

23.

Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017;7(1):1529. https://doi.org/10.1038/s41598-017-01751-y.CrossRefPubMedPubMedCentral

24.

Shou D, Luo Q, Tang W, Cao C, Huang H, Chen H, et al. Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota. J Gastroenterol Hepatol. 2023;38(12):2195–205. https://doi.org/10.1111/jgh.16359.CrossRefPubMed

25.

Zhu X, Zhao L, Lei L, Zhu Y, Xu J, Liu L. Fecal microbiota transplantation ameliorates abdominal obesity through inhibiting microbiota-mediated intestinal barrier damage and inflammation in mice. Microbiol Res. 2024;282:127654. https://doi.org/10.1016/j.micres.2024.127654.CrossRefPubMed

26.

Soderborg TK, Clark SE, Mulligan CE, Janssen RC, Babcock L, Ir D, et al. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun. 2018;9(1):4462. https://doi.org/10.1038/s41467-018-06929-0.CrossRefPubMedPubMedCentral

27.

Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, et al. Fecal microbiota transplant from human to mice gives insights into the role of the gut microbiota in non-alcoholic fatty liver disease (NAFLD). Microorganisms. 2021;9(1):199. https://doi.org/10.3390/microorganisms9010199.CrossRefPubMedPubMedCentral

28.

Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metab. 2019;30(4):675-688.e7. https://doi.org/10.1016/j.cmet.2019.08.018.CrossRefPubMed

29.

Lee DH, Jee JJ, Lee YS, Kim DY, Bang JY, Lee HW, et al. Fecal microbiota transplantation improves hepatic fibro-inflammation via regulating oxidative stress in experimental NASH. Dig Liver Dis. 2023;55(11):1521–32. https://doi.org/10.1016/j.dld.2023.06.015.CrossRefPubMed

30.

García-Lezana T, Raurell I, Bravo M, Torres-Arauz M, Salcedo MT, Santiago A, et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology. 2018;67(4):1485–98. https://doi.org/10.1002/hep.29646.CrossRefPubMed

31.

Mitsinikos FT, Chac D, Schillingford N, DePaolo RW. Modifying macronutrients is superior to microbiome transplantation in treating nonalcoholic fatty liver disease. Gut Microbes. 2020;12(1):1–16. https://doi.org/10.1080/19490976.2020.1792256.CrossRefPubMed

32.

Yadegar A, Pakpoor S, Ibrahim FF, Nabavi-Rad A, Cook L, Walter J, et al. Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Cell Host Microbe. 2023;31(5):695–711. https://doi.org/10.1016/j.chom.2023.03.019.CrossRefPubMedPubMedCentral

33.

Xue L, Deng Z, Luo W, He X, Chen Y. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Cell Infect Microbiol. 2022;4(12):759306. https://doi.org/10.3389/fcimb.2022.759306.CrossRef

34.

Abenavoli L, Maurizi V, Rinninella E, Tack J, Di Berardino A, Santori P, et al. Fecal Microbiota Transplantation in NAFLD Treatment. Medicina (Kaunas). 2022;58(11):1559. https://doi.org/10.3390/medicina58111559.CrossRefPubMed

35.

Wynn AB, Beyer G, Richards M, Ennis LA. Procedure, Screening, and Cost of Fecal Microbiota Transplantation. Biomedicines. 2023;9:2480. https://doi.org/10.3390/biomedicines11092480.CrossRef

36.

Aràjol C, Aira Gómez A, González-Suárez B, Casals-Pascual C, Martí Martí S, Domínguez Luzón MÁ, et al. Donor selection for faecal microbiota transplantation. Consensus document of the Catalan Society of Gastroenterology and the Catalan Society of Infectious Diseases and Clinical Microbiology. Gastroenterol Hepatol. 2021;44(2):175–80. https://doi.org/10.1016/j.gastrohep.2020.07.027.CrossRefPubMed

37.

Information Pertaining to Additional Safety Protections Regarding Use of Fecal Microbiota for Transplantation — Screening and Testing of Stool Donors for Multi-drug Resistant Organisms —FDA. Available online: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-additional-safety-protections-regarding-use-fecal-microbiota-transplantation (Accessed on 25 March 2024).

38.

Wang Y, Zhang S, Borody TJ, Zhang F. Encyclopedia of fecal microbiota transplantation: A review of effectiveness in the treatment of 85 diseases. Chin Med J (Engl). 2022;135(16):1927–39. https://doi.org/10.1097/CM9.0000000000002339.CrossRefPubMed

39.

Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019;118(Suppl 1):S23–31. https://doi.org/10.1016/j.jfma.2018.08.011.CrossRefPubMed

40.

Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021;53(1):33–42. https://doi.org/10.1111/apt.16148.CrossRefPubMed

41.

Varga A, Kocsis B, Sipos D, Kása P, Vigvári S, Pál S, et al. How to Apply FMT More Effectively, Conveniently and Flexible – A Comparison of FMT Methods. Front Cell Infect Microbiol. 2021;4(11):657320. https://doi.org/10.3389/fcimb.2021.657320.CrossRef

42.

Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, et al. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil. 2022;28(1):28–42. https://doi.org/10.5056/jnm21221.CrossRefPubMedPubMedCentral

43.

Park SY, Seo GS. Fecal microbiota transplantation: Is it safe? Clin Endosc. 2021;54(2):157–60. https://doi.org/10.5946/ce.2021.072.CrossRefPubMedPubMedCentral

44.

Fecal Microbiota for Transplantation: Safety Alert - Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms. —FDA. Available online: https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission (Accessed on 25 March 2024).

45.

Bibbò S, Settanni CR, Porcari S, Bocchino E, Ianiro G, Cammarota G, et al. Fecal microbiota transplantation: Screening and selection to choose the optimal donor. J Clin Med. 2020;9(6):1757. https://doi.org/10.3390/jcm9061757.CrossRefPubMedPubMedCentral

46.

Orenstein R, Dubberke E, Hardi R, Ray A, Mullane K, Pardi DS, et al. Safety and Durability of RBX2660 (microbiota suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis. 2016;62(5):596–602. https://doi.org/10.1093/cid/civ938.CrossRefPubMed

47.

Laffin M, Madsen KL. Fecal Microbial Transplantation in Inflammatory Bowel Disease: A Movement Too Big to Be Ignored. Clin Pharmacol Ther. 2017;102(4):588–90. https://doi.org/10.1002/cpt.747.CrossRefPubMed

48.

Fralick M, Avorn J, Franklin JM, Abdurrob A, Kesselheim AS. Application and impact of run-in studies. J Gen Intern Med. 2018;33(5):759–63. https://doi.org/10.1007/s11606-018-4344-7.CrossRefPubMedPubMedCentral

49.

Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, et al. Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology. 2022;75(6):1647–61. https://doi.org/10.1002/hep.32315.CrossRefPubMed

50.

Reigadas E, Bouza E, Olmedo M, Vázquez-Cuesta S, Villar-Gómara L, Alcalá L, et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. J Hosp Infect. 2020;105(2):319–24. https://doi.org/10.1016/j.jhin.2019.12.022.CrossRefPubMed

51.

Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral capsule– vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: A randomized clinical trial. JAMA. 2017;318(20):1985–93. https://doi.org/10.1001/jama.2017.17077.CrossRefPubMedPubMedCentral

52.

Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Levin J, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14(1):134. https://doi.org/10.1186/s12916-016-0680-9.CrossRefPubMedPubMedCentral

53.

Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, et al. Microbial Metabolites: Critical Regulators in NAFLD. Front Microbiol. 2020;7(11):567654. https://doi.org/10.3389/fmicb.2020.567654.CrossRef

54.

EbrahimzadehLeylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, et al. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis. 2020;39(4):613–27. https://doi.org/10.1007/s10096-019-03746-1.CrossRef

55.

Pinheiro I, Barberá A, Raurell I, Estrella F, de Leeuw M, Bolca S, et al. A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. Biomedicines. 2022;10(5):1191. https://doi.org/10.3390/biomedicines10051191.CrossRefPubMedPubMedCentral

56.

Lagier JC, Dubourg G, Million M, Cadoret F, Bilen M, Fenollar F, et al. Culturing the human microbiota and culturomics. Nat Rev Microbiol. 2018;16:540–50. https://doi.org/10.1038/s41579-018-0041-0.CrossRefPubMed

57.

Quaranta G, Ianiro G, De Maio F, Guarnaccia A, Fancello G, Agrillo C, et al. “bacterial Consortium”: A Potential Evolution of Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection. Biomed Res Int. 2022;8(2022):5787373. https://doi.org/10.1155/2022/5787373.CrossRef

58.

El Hage R, Hernandez-Sanabria E, Calatayud Arroyo M, Props R, Van De Wiele T. Propionate-producing consortium restores antibiotic-induced dysbiosis in a dynamic in vitro model of the human intestinal microbial ecosystem. Front Microbiol. 2019;31(10):1206. https://doi.org/10.3389/fmicb.2019.01206.CrossRef

59.

Aggarwala V, Mogno I, Li Z, Yang C, Britton GJ, Chen-Liaw A, et al. Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nat Microbiol. 2021;6(10):1309–18. https://doi.org/10.1038/s41564-021-00966-0.CrossRefPubMedPubMedCentral

60.

Kobyliak N, Abenavoli L, Mykhalchyshyn G, Kononenko L, Boccuto L, Kyriienko D, et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: Evidence from a randomized clinical trial. J Gastrointestin Liver Dis. 2018;27(1):41–9. https://doi.org/10.15403/jgld.2014.1121.271.CrossRefPubMed

61.

Chen X, Mendes BG, Alves BS, Duan Y. Phage therapy in gut microbiome. Prog Mol Biol Transl Sci. 2023;201:93–118. https://doi.org/10.1016/bs.pmbts.2023.04.005.CrossRefPubMed

62.

Gan L, Feng Y, Du B, Fu H, Tian Z, Xue G, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023;14(1):3215. https://doi.org/10.1038/s41467-023-39028-w.CrossRefPubMedPubMedCentral

Title: Assessing the Therapeutic Potential of Fecal Microbiota Transplantation in Steatotic Liver Disease: Current Insights and Future Pathways
Authors: Carolina Jiménez-González
Ignacio Vallejo
David Sordo
Juan Manuel Medina-Méndez
Marta Alonso-Peña
Javier Crespo
Publication date: 29-07-2024
Publisher: Springer US
Keywords: Metabolic Dysfunction-Associated Steatotic Liver Disease
Gastrointestinal Microbiota
Metabolic Dysfunction-Associated Steatohepatitis
Published in: Current Hepatology Reports
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00670-7

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

ERS Congress 2024

Springer Medicine

Assessing the Therapeutic Potential of Fecal Microbiota Transplantation in Steatotic Liver Disease: Current Insights and Future Pathways

Abstract

Purpose of Review

Recent Findings

Summary

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

ERS Congress 2024

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials